Geistlich Pharma AG (Wolhusen, Switzerland) funded the study and provided 2% taurolidine and 0.9% saline solution. The funder had no involvement in the study design, collection, analysis and interpretation of data, writing of the report and the decision to submit the article for publication.
| INTRODUCTION
Home parenteral nutrition entered the clinical arena in the late 1960s and has since remained the mainstay for the support of patients with chronic intestinal failure. [1] [2] [3] This type of nutritional support requires the presence of a central venous access device (CVAD), most commonly a catheter, for the supplementation of nutrients and fluids at home. Despite ongoing technical improvements, catheter-related bloodstream infections (CRBSIs) remain the Achilles' heel of home parenteral nutrition treatment. 4 The reported CRBSI incidence ranges from 0.38 to 2.99 CRBSI per 1000 catheter days and accounts for approximately 70% of all home parenteral nutrition-related hospital admissions. 5, 6 As such, CRBSIs compromise venous access and patient survival, and may lead to home parenteral nutrition failure because of a permanent loss of vascular access.
Strict adherence to aseptic protocols when handling CVADs remains the key strategy to prevent CRBSIs. The use of anti-microbial catheter lock solutions has also been advocated, but the search for the optimal locking agent remains ongoing. 4 Several catheter lock solutions have been studied for their effectiveness in preventing CRBSIs, including antiseptic agents, antibiotics and anticoagulants. Most catheter lock solutions have been abandoned because of side effects, concern about the development of microbial resistance or mere lack of effect. 4 Historically, heparin was the most commonly used catheter lock solution, also because of the supposed need for an anticoagulant. However, its use potentially increases the risk for CRBSIs by promoting intraluminal biofilm formation and is no longer recommended. 4, 7, 8 In 1998, use of the broadspectrum antiseptic agent taurolidine as catheter lock solution was first described. 9 The background for the effect of taurolidine is that this agent prevents endoluminal biofilm formation by inhibiting microbial adhesion to the inner surface of the catheter and that it destroys microbial cell membranes and toxins. [10] [11] [12] [13] Subsequent studies and a meta-analysis confirmed that taurolidine, when compared to heparin, decreases CRBSI incidence in patients with catheters. [14] [15] [16] None of these previous studies, however, discriminated between beneficial effects of taurolidine and/or the detrimental effects of heparin. Currently, 0.9% saline solution is commonly used as an alternative to taurolidine because of its safety profile and low cost, despite a lack of evidence from well-powered studies. 4, 17 These issues, and the fact that it remains unclear whether the use of taurolidine should be restricted to patients with a high risk for CRBSIs, urged us to test the hypothesis that 2% taurolidine is a superior catheter lock solution to 0.9% saline in preventing CRBSIs. This hypothesis was tested in home parenteral nutrition patients who were stratified in two patient categories. Patients in the first group had a new catheter without any biofilm, and in this group, the potency of taurolidine to prevent the development of biofilms (and hence CRBSIs) could be shown.
Patients in the second group had previously experienced CRBSIs and had a pre-existing CVAD that possibly had acquired an infection-promoting biofilm on the inner catheter surface. These patients were at a higher risk to develop a CRBSI.
| METHODS

| Study oversight
This multicentre, double-blinded superiority trial was conducted in six referral centres (Denmark, Israel, Italy, the Netherlands and the United Kingdom), in which home parenteral nutrition patients were randomly assigned to use either a catheter lock solution containing 2% taurolidine or 0.9% saline for 1 year. The study design was conceived by the final author and followed close consultation with members of the Home Artificial Nutrition and Chronic Intestinal
Failure special interest group of the European Society for Clinical
Nutrition and Metabolism. The institutional review board or ethics committee at each participating centre approved the study protocol.
Geistlich Pharma AG (Wolhusen, Switzerland) provided 2% taurolidine (TauroSept) and 0.9% saline solution, but had no role in the study design, data analysis or preparation of the manuscript. Acromion GmbH (Frechen, Germany), an independent contract research organisation, provided data management. Acromion GmbH and the first author performed the data analyses. The CONSORT guidelines were followed to report this study. 
| Participants
| Randomisation and blinding
Patients were screened for eligibility during regular outpatient clinical check-ups or during hospitalisation. After the local principal investigator determined eligibility and obtained written informed consent, the patients were stratified into the new catheter group or pre-existing catheter group, and randomised according to a random computer-permuted block scheme (1:1, with block sizes of four patients) to either 2% taurolidine or 0.9% saline by the sponsor in a validated environment. All vials were identical in appearance, smell and method of administration. All patients, investigators and site personnel as well as persons involved in field monitoring, data handling or the conduct of the trial were blinded to the randomisation data and the trial medication.
| Study treatment
Patients or caregivers were instructed according to local training procedures on how to instil the lock solution at home. The catheter lock solutions were stored at room temperature. Each time an infusion of parenteral nutrition or fluids was completed, the CVAD was flushed with 10 mL sterile physiological saline solution. Subsequently, an identical vial containing 5 mL 2% taurolidine or 0.9% saline solution was instilled into the CVAD. The frequency of administration depended on the patient's parenteral nutrition schedule and ranged from twice per week to once daily. Patients were seen every 3 months by an investigator during regular outpatient clinic visits or during unscheduled visits and hospitalisations. At these check-ups, CVAD-related complications, concomitant medication, catheter function, catheter exit sites and adverse events were assessed. In cases where a CRBSI was proven during the study, the patient was withdrawn from the trial after a final visit procedure. and/or C-reactive protein rise), in the absence of any other apparent source of infection than the CVAD. 4 In this event, paired quantitative or qualitative blood cultures from the CVAD and from a peripheral vein were taken. A CRBSI was proven when at least one blood culture was positive from the CVAD or a peripheral vein. In (Table S2) .
| Outcomes
The primary analysis was tested in a modified intention-to-treat population, which included all randomised patients exposed to taurolidine or saline and who had at least one effectiveness assessment available. Furthermore, a per-protocol analysis was performed in which, in addition to the modified intention-to-treat criteria, patients had to meet the eligibility criteria and complete the trial for planned visits with complete test results in accordance with all relevant aspects of the protocol. Safety analyses were based on all randomised patients. Baseline characteristics, effectiveness and safety measurements were summarised using descriptive statistical methods. Time-to-event endpoints were described by Kaplan-Meier curves and were compared using a log-rank test. Costs were based on Dutch prices and consisted of catheter lock solution costs and CRBSI resource use costs (hospitalisations, unscheduled outpatient clinic consultations, CVAD changes and drug treatment). 22, 23 The mean costs per patient were calculated by means of an independent samples t test after bootstrapping (1000 simulations) with 95% confidence intervals. All other outcomes were analysed using a twosided Fisher exact test. In a post hoc analysis, the results of both groups were summarised in a combined group analysis. All analyses, except for the primary analysis, were performed using Statistical Analysis System software, version 9.4.
| RESULTS
| Study population
Between (Table 1) . A total of 85 patients were included in the per-protocol analysis.
| Outcomes
In the new catheter group, three CRBSIs occurred during 10 248
catheter days in the taurolidine arm, while in the saline arm, 13
CRBSIs occurred in 8708 catheter days, resulting in 0.29 and 1.49
CRBSIs/1000 catheter days for taurolidine and saline respectively (relative risk, 0.20; 95% CI, 0.04-0.71; P = 0.009). The cumulative proportion of CRBSI-free patients after 1 year was 89% for taurolidine and 43% for saline (P = 0.002) ( Figure 2 ). The remaining secondary outcomes were non-significant between taurolidine and saline. The results of the per-protocol analysis were generally similar to the modified intention-to-treat analysis (Table S1 and Figure S1 ).
In the pre-existing catheter group, two CRBSIs occurred during 5070 catheter days in the taurolidine arm, while in the saline arm, five CRBSI occurred in 3785 catheter days, resulting in 0.39 and 1.32 CRBSIs/1000 catheter days for taurolidine and saline respectively (relative risk, 0.30; 95% CI, 0.03-1.82; P = 0.25). The remaining secondary outcomes were non-significant between taurolidine and saline. The results of the per-protocol analysis were generally similar to the modified intention-to-treat analysis (Table S1 and Figure S1 ).
In the combined group analyses, five CRBSIs occurred during 15 318 catheter days in the taurolidine arm, while in the saline arm, 18 CRBSIs occurred in 12 493 catheter days, resulting in 0.33 and 1.44 CRBSI/1000 catheter days for taurolidine and saline respectively (relative risk, 0.23; 95% CI, 0.07-0.63; P = 0.002) ( Table 2 ). The cumulative proportion of CRBSI-free patients after 1 year was 88%
in the taurolidine arm and 49% in the saline arm (P = 0.002) (Figure 2) . The number of patients with a CRBSI-related catheter removal was two (4%) in the taurolidine arm and eight (16%) in the saline arm (P = 0.049). The time to CVAD removal due to CRBSI was significantly prolonged in the taurolidine arm (P = 0.02) (Figure 2 ). The remaining secondary outcomes were non-significant between taurolidine and saline. The per-protocol analyses were generally similar to the modified intention-to-treat analyses (Table S1 and Figure S1 ).
| CRBSI-causing microorganisms
During the study, all CRBSIs were proven by at least one positive blood culture. In the taurolidine arm, three patients experienced a monobacterial Gram-positive CRBSI, one patient a polybacterial CRBSI and one patient had an episode with a microorganism that was not specified (Table 3 ). In the saline arm, six monobacterial
Gram-positive and eight Gram-negative CRBSIs occurred. One patient experienced a polybacterial CRBSI, one patient had an isolated fungaemia and two patients experienced an episode with a microorganism that was not specified. The CVAD salvage rate in patients with a CRBSI was 60% for taurolidine and 56% for saline.
| Adverse events
A total of 71 (68%) patients reported adverse events. Except for occurrence of CRBSIs, there was no difference in adverse events between taurolidine and saline (Table 4) . CVAD-related complications were the most frequently reported adverse event. Drug-related adverse events were rare and either mild to moderate. Two patients deceased in the taurolidine arm, but neither demise was considered to be drug-related.
| Resource use and costs
The mean costs per patient were comparable for taurolidine ($4422) and saline ($4454) (Table 5) 
| Post hoc analysis new catheter group
Of 71 patients included in the new catheter group, 27 (38%) had a history of at least one CRBSI. Of the remaining 44 patients without a history of CRBSIs, 13 (72%) in the taurolidine and 13 (50%) in the saline arm, respectively, were home parenteral nutrition-naïve at inclusion. In the group of patients with a history of CRBSIs, three (17%) in the taurolidine arm and four (44%) in the saline arm experienced a new CRBSI during the study (P = 0.22) (Table 6 ). Notably, of 44 patients with no record of CRBSIs in the past, none of the patients in the taurolidine arm experienced a CRBSI, while nine patients (35%) in the saline arm experienced their first CRBSI during the study (P = 0.01). Of these nine patients, five patients were home parenteral nutrition-naïve. 12 refused to participate 7 did not meet in/exclusion criteria: 2 received treatment with systemic antibiotics 2 were hypersensitive to taurolidine 1 used high-dose thrombolytic therapy 1 had elevated C-reactive protein 1 was on short-term home parenteral nutrition F I G U R E 1 Enrollment and follow-up. *Patients were excluded from the modified intention-to-treat analysis because no effectiveness assessments were available after the baseline visit.
† Patients were excluded from the per-protocol analysis because they either did not meet eligibility criteria or did not complete the trial before the planned visits with complete test results in accordance with the protocol. Some patients were excluded from the per-protocol analysis for more than one reason but were included in only one exclusion category
| DISCUSSION
This study is by far the largest multicentre double-blind randomised clinical trial ever performed in the home parenteral nutrition setting,
and the first to demonstrate that 2% taurolidine prevents the development of CRBSIs in home parenteral nutrition support, when compared with 0.9% saline. Specifically in the new catheter group, the CRBSI rate was significantly decreased by taurolidine, and the time 
Groups combined
Groups combined
Pre-existing catheter group New catheter group F I G U R E 2 Kaplan-Meier survival curves of modified intention-to-treat population. CRBSI, catheter-related bloodstream infection; CVAD, catheter-related access device. Kaplan-Meier survival curves presenting the time to CRBSIs (A-C) and time to CVAD removals due to CRBSIs (D-F) with CVADs locked with 2% taurolidine (green continuous line) versus 0.9% saline (blue interrupted line) in the new catheter group, preexisting catheter group, and the groups combined. Survival curves were compared using log-rank testing intraluminal layers have been shown to be important precursors for the development of CRBSIs in long-term CVADs. 10, 24 If this were the case, these findings would underscore the need for strategiessuch as taurolidine locking-that aim to prevent intraluminal biofilm formation in long-term CVADs. [10] [11] [12] In the combined group analysis, the CRBSI rate was lowered by taurolidine as well, and additional beneficial effects on (time to) CVAD removals due to CRBSIs were observed.
It is important to emphasise that adequate catheter care with strict adherence to aseptic protocols when handling CVADs remains the key strategy to prevent CRBSIs, whereas catheter locking only comes second in line in this respect. Our results suggest that, in the most likely clinical setting, that is, home parenteral nutrition patients starting locking of a new catheter, taurolidine seems most effective and as such this agent promises to be an important addition to our armamentarium to prevent CRBSIs.
When implementing any new preventive strategy, cost-effectiveness is an issue on the population level, especially since the background risk for the development of CRBSIs is a quality indicator for the care provided by an intestinal failure centre. This implies that to be cost-effective in a centre with a very low background risk for
CRBSIs, a substantial number of patients will receive this locking solution who will never develop an episode of CRBSI, while in those centres with a high background risk for CRBSIs, cost-effectiveness will be easily achieved. At the individual patient level, however, the prevention of any episode of CRBSI may be crucial in light of the associated morbidity, risk for loss of options to obtain venous access and mortality. In this vein, it is also important to mention that so far, evidence for serious side effects of long-term catheter locking with taurolidine in the clinical setting is lacking. 25, 26 This finding is corroborated by the absence of such deleterious effects when taurolidine is infused in large volumes (>1 L/d) in humans in the setting of treatment of oncologic diseases. 27, 28 In light of the trial results, it is our opinion that there is no reason to withhold taurolidine in any patient with a new CVAD that is without biofilm for CRBSI prevention.
However, the counterbalance of the previously mentioned issues and the consideration to implement an effective preventive strategy in this specific patient category may eventually vary per treating specialist team. As previously stated, our study results preclude any conclusions on the use of taurolidine in high-risk patients who already had a CVAD in place, be it due to statistical issues (underpowering) and/or because of decreased effectiveness in CVADs with a preexisting intraluminal biofilm.
It is often difficult, if not impossible, to discriminate between CVAD occlusions (either thrombotic or due to parenteral nutrition components (especially lipids)) on one side, and venous thrombotic occlusions on the other. In this study, taurolidine showed that no additional effect on CVAD occlusion rates compared to saline. In (25) 6 (17) 6 (38) 6 (40) 15 (29) 12 (24) Very satisfied 15 (42) 12 (34) 7 (44) 3 (20) 22 (42) 15 (30) CI, confidence interval; CRBSI, catheter-related bloodstream infection; CVAD, central venous access device; IQR, interquartile range. For exit site infections, data were missing for one patient in the saline arm of the pre-existing catheter group. For CVAD occlusions, data were missing for one patient in the saline arm of the pre-existing catheter group. For patient satisfaction in the new catheter group, data were missing for 12 and 17 patients in the taurolidine and saline groups, respectively. For patient satisfaction in the pre-existing catheter group, data were missing for three and six patients in the taurolidine and saline groups respectively.
addition, a meta-analysis comparing 1.35% taurolidine and 4% citrate with heparin did not find any beneficial effects on CVAD occlusion rates either. 15 However, some in vitro and retrospective studies have reported beneficial effects of taurolidine over heparin, without using any concomitant anticoagulant protection. 11, 25, 29, 30 This decrease in CVAD occlusions may be explained by a parallel decrease in CRBSIs, and thus of infection-induced activation of the coagulation system, rather than anti-coagulant properties of taurolidine.
Despite prolonged use of taurolidine, some patients still developed CRBSIs. One reason might be breaches or non-compliance of patients or caregivers to antiseptic CVAD care protocols. Another 
Staphylococcus aureus 1 2
Staphylococcus epidermidis 1 4
Streptococcus salivarius 1 0
Species not specified 1 0
Total 4 7
Gram-negative -no. of microorganisms In the taurolidine and saline group, respectively two (Streptococcus salivarius and Neiserna elongata) and three (Acinetobacter ursingii, Stenotrophomonas maltophilia and Staphylococcus epidermidis) microorganisms were grown from one blood culture. c A positive blood culture was reported; however, the microorganism involved was not documented. Costs (USD) were compared using an independent samples t test after bootstrapping (1000 simulations). found no evidence for altered bacterial susceptibility to taurolidine. 14, 31 This was not unexpected, given taurolidines' non-specific chemical aseptic mode of action. To date, no microbial resistance to taurolidine has been reported. 11, 15, 32 The CVAD salvage rate of 60% in patients with a CRBSI was similar in both arms and is comparable to rates observed in previous studies (55%-80%). 6, 33, 34 With regard to the microbial pathogens leading to CRBSIs, several cohort studies reported a preponderance of infections caused by Gram-positive (60%-80%) over Gram-negative bacteria (20%-40%). 4, 19, 35, 36 One meta-analysis showed that the use of taurolidine significantly decreased CRBSIs caused by Gramnegative bacteria, whereas CRBSIs from Gram-positive organisms did not change. 15 In this trial, there was no difference in the type of pathogens leading to CRBSIs between taurolidine and saline. A clear limitation of this trial is the inclusion of the pre-existing catheter group. The inclusion was partly hampered by participation of only six instead of seven centres due to local administrative issues, and because one of the six remaining centres was unable to include high-risk patients due to previous use of taurolidine in the CVADs. This latter group, in whom any beneficial effect of a CRBSIpreventing measure might be expected to be most noticeable, was based on expert opinion, since no strict criteria for high-risk patients have been defined in the home parenteral nutrition literature. The assumptions on which this group was based may have been too strict (eg CVADs ≥6 months in place and no antibiotic therapy <2 months prior to trial inclusion), resulting in a lower than expected number of high-risk patients in the study, and subsequently an underpowered group. In addition, some patients in the pre-existing catheter group were improperly included as these patients did not have CRBSIs in their medical history and therefore did not meet the criteria for being a high-risk patient. A second limitation of our study is that it was performed against the background of a certain infectious complication rate. As mentioned, this does not necessarily prove that the cost-effectiveness of the strategy to use taurolidine also pertains to centres with an extremely low CRBSI rate.
Our study outcomes may be relevant for other fields (haemodialysis, oncology) where reliable venous access is paramount. Apart from the 2% taurolidine formulation that was used in this study, various other combinations of 1.35% taurolidine and anticoagulants (citrate, heparin or urokinase) are available. These agents are intended for use in areas with a risk for thrombotic occlusion, such as haemodialysis, where blood necessarily enters the catheter. In the absence of adequately powered studies comparing taurolidine formulations with and without concomitant anticoagulants, we can only speculate about their effectiveness in the setting of home parenteral nutrition.
Future research should focus on additional strategies to minimise CRBSI rates, apart from patient and caregiver training in catheter handling, including optimisation of (taurolidine-containing) locking formulations and its selection in subgroups of patients with a higher risk for CBRSIs, and the use of devices such as antimicrobial catheter caps. 37 In conclusion, using 2% taurolidine as catheter lock solution decreases the risk for CRBSIs in home parenteral nutrition patients with a new catheter compared with 0.9% saline. It remains unclear whether this also applies for patients with a supposed high CRBSI risk who already have had a catheter in place. Given its favourable safety and cost profile, our study supports the use of 2% taurolidine locking for CRBSI prevention in home parenteral nutrition care.
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